CMML
MCID: CHR285
MIFTS: 56

Chronic Myelomonocytic Leukemia (CMML) malady

Categories: Rare diseases, Cancer diseases, Blood diseases

Aliases & Classifications for Chronic Myelomonocytic Leukemia

Aliases & Descriptions for Chronic Myelomonocytic Leukemia:

Name: Chronic Myelomonocytic Leukemia 38 50 56
Leukemia, Myelomonocytic, Chronic 50 29 69
Myelomonocytic Leukemia, Chronic 13
Leukemia Myelomonocytic Chronic 52
Cmml 56

Characteristics:

Orphanet epidemiological data:

56
chronic myelomonocytic leukemia
Age of onset: Adult;

Classifications:



External Ids:

Orphanet 56 ORPHA98823
UMLS via Orphanet 70 C0023480
ICD10 via Orphanet 34 C93.1
MESH via Orphanet 43 D015477
ICD10 33 C93.1

Summaries for Chronic Myelomonocytic Leukemia

MalaCards based summary : Chronic Myelomonocytic Leukemia, also known as leukemia, myelomonocytic, chronic, is related to liver disease and leukemia, acute myelomonocytic, somatic, somatic, and has symptoms including fatigue, fever and night sweats. An important gene associated with Chronic Myelomonocytic Leukemia is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Chromatin Regulation / Acetylation and Tyrosine Kinases / Adaptors. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and monocytes, and related phenotypes are cellular and growth/size/body region

Wikipedia : 71 Chronic myelomonocytic leukaemia (CMML) is a type of leukaemia, which are cancers of the blood-forming... more...

Related Diseases for Chronic Myelomonocytic Leukemia

Diseases related to Chronic Myelomonocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)
id Related Disease Score Top Affiliating Genes
1 liver disease 29.0 ETV6 FLT3 JAK2 RUNX1
2 leukemia, acute myelomonocytic, somatic, somatic 11.7
3 myelodysplastic syndrome 11.4
4 pdgfrb-associated chronic eosinophilic leukemia 11.1
5 leukemia 11.0
6 myelodysplastic myeloproliferative cancer 11.0
7 myeloid leukemia 10.4
8 autosomal dominant proximal renal tubular acidosis 10.1 ETV6 PDGFRB
9 regional odontodysplasia 10.1 ASXL1 SETBP1 TET2
10 mastocytosis 10.1
11 comt-related pain sensitivity alteration 10.1 ETV6 RUNX1
12 presynaptic congenital myasthenic syndromes 10.1 EZH2 JAK2
13 lymphomatoid granulomatosis 10.1 ETV6 RUNX1
14 systemic mastocytosis 10.1
15 refractory anemia 10.1
16 nephrolithiasis 10.1 SETBP1 TET2
17 osteogenesis imperfecta, type viii 10.1 JAK2 TET2
18 circumscribed cutaneous aplasia of the vertex 10.1 ASXL1 SETBP1
19 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 10.1 JAK2 PDGFRB
20 atypical chronic myeloid leukemia 10.1
21 myelofibrosis 10.1
22 acute leukemia 10.0
23 thrombocytopenia 10.0
24 myeloproliferative neoplasm 10.0
25 spondylocostal dysostosis 2 10.0 JAK2 SETBP1
26 basilar artery insufficiency 10.0 ASXL1 JAK2 TET2
27 montefiore syndrome 10.0 ETV6 FLT3
28 chronic lymphocytic leukemia 10.0
29 lymphoma 10.0
30 chronic neutrophilic leukemia 10.0
31 lymphoblastic leukemia 10.0
32 sarcoma 10.0
33 multiple myeloma 10.0
34 unilateral hemispheric polymicrogyria 10.0 FLT3 RUNX1
35 acute respiratory distress syndrome 9.9 FLT3 JAK2
36 von hippel anomaly 9.9 ASXL1 JAK2 RUNX1 TET2
37 hematopoietic stem cell transplantation 9.9
38 vasculitis 9.9
39 purpura 9.9
40 histiocytosis 9.9
41 temporomandibular ankylosis 9.9 ASXL1 JAK2 PDGFRB TET2
42 focal epilepsy 9.9 ETV6 JAK2 PDGFRB TET2
43 adducted thumbs dundar type 9.9 ETV6 FLT3 RUNX1
44 acute myocardial infarction 9.9 ETV6 FLT3 RUNX1
45 neuromyelitis optica 9.8 FLT3 JAK2 TET2
46 hyperphosphatasia with mental retardation syndrome 2 9.8 ETV6 FLT3 RUNX1
47 pyoderma 9.8
48 polyneuropathy 9.8
49 chronic graft versus host disease 9.8
50 monocytic leukemia 9.8

Graphical network of the top 20 diseases related to Chronic Myelomonocytic Leukemia:



Diseases related to Chronic Myelomonocytic Leukemia

Symptoms & Phenotypes for Chronic Myelomonocytic Leukemia

UMLS symptoms related to Chronic Myelomonocytic Leukemia:


fatigue, fever, night sweats

MGI Mouse Phenotypes related to Chronic Myelomonocytic Leukemia:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.26 ASXL1 DNMT3A ETV6 EZH2 FLT3 HIP1
2 growth/size/body region MP:0005378 10.22 KDM6A PDGFRB RUNX1 TET2 ASXL1 DNMT3A
3 endocrine/exocrine gland MP:0005379 10.19 ASXL1 DNMT3A ETV6 EZH2 FLT3 HIP1
4 homeostasis/metabolism MP:0005376 10.17 EZH2 FLT3 HIP1 JAK2 KDM6A PDGFRB
5 hematopoietic system MP:0005397 10.16 HIP1 JAK2 KDM6A PDGFRB RUNX1 TET2
6 immune system MP:0005387 10.1 ASXL1 ETV6 EZH2 FLT3 HIP1 JAK2
7 mortality/aging MP:0010768 10.1 DNMT3A ETV6 EZH2 FLT3 HIP1 JAK2
8 cardiovascular system MP:0005385 10.08 DNMT3A ETV6 EZH2 KDM6A PDGFRB RUNX1
9 embryo MP:0005380 10.05 DNMT3A ETV6 EZH2 JAK2 KDM6A PDGFRB
10 neoplasm MP:0002006 9.86 ASXL1 ETV6 EZH2 FLT3 HIP1 JAK2
11 liver/biliary system MP:0005370 9.77 ASXL1 HIP1 JAK2 RUNX1 TET2
12 no phenotypic analysis MP:0003012 9.7 DNMT3A ETV6 EZH2 FLT3 KDM6A RUNX1
13 normal MP:0002873 9.56 ETV6 EZH2 HIP1 JAK2 KDM6A PDGFRB
14 skeleton MP:0005390 9.23 PDGFRB RUNX1 ASXL1 EZH2 FLT3 HIP1

Drugs & Therapeutics for Chronic Myelomonocytic Leukemia

Drugs for Chronic Myelomonocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
3
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-98-1 2478
4
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
7 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
8 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
10
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
11
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
12
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
13
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
14
Idarubicin Approved Phase 3,Phase 1,Phase 2 58957-92-9 42890
15
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
16
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
17
Ofloxacin Approved Phase 3 82419-36-1 4583
18
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
19
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
20
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
21
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
22
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1 83-43-2 6741
23
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1 50-24-8 5755
24
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
25
Clofarabine Approved, Investigational Phase 3,Phase 2,Phase 1 123318-82-1 119182
26
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
27
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
28
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
29
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
30
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
31
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
32
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
33
Asparaginase Approved Phase 3 9015-68-3
34
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
35
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
36
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
37
Thioguanine Approved Phase 3 154-42-7 2723601
38
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
39
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
40
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
41
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
42
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
43
Morphine Approved, Investigational Phase 3 57-27-2 5288826
44
Ondansetron Approved Phase 3,Phase 2,Phase 1 99614-02-5 4595
45
Dalteparin Approved Phase 3 9041-08-1
46
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
47
Ephedrine Approved Phase 3 299-42-3 9294
48
Pseudoephedrine Approved Phase 3 90-82-4 7028
49
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
50
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965

Interventional clinical trials:

(show top 50) (show all 473)
id Name Status NCT ID Phase
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
2 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4
3 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3
4 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3
5 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3
6 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
8 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3
9 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3
10 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
11 Decitabine Versus Supportive Care in Adults With Advanced-stage MDS Completed NCT00043381 Phase 3
12 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3
13 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3
14 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3
15 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
16 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
17 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3
18 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3
19 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
20 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
21 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
22 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
23 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
24 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
25 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3
26 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
27 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3
28 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
29 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
30 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
31 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
32 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3
33 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3
34 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3
35 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3
36 Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Recruiting NCT02907359 Phase 3
37 Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Recruiting NCT02214407 Phase 3
38 Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission Recruiting NCT01757535 Phase 3
39 Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Recruiting NCT00619879 Phase 3
40 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT02085408 Phase 3
41 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Active, not recruiting NCT01241500 Phase 3
42 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Active, not recruiting NCT00843882 Phase 3
43 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3
44 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
45 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3
46 Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) Terminated NCT00109538 Phase 3
47 Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis Terminated NCT01749111 Phase 3
48 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3
49 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3
50 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases Terminated NCT00450450 Phase 3

Search NIH Clinical Center for Chronic Myelomonocytic Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Myelomonocytic Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Chronic Myelomonocytic Leukemia:
Hemacord
Embryonic/Adult Cultured Cells Related to Chronic Myelomonocytic Leukemia:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD PMIDs: 9828244

Genetic Tests for Chronic Myelomonocytic Leukemia

Genetic tests related to Chronic Myelomonocytic Leukemia:

id Genetic test Affiliating Genes
1 Chronic Myelomonocytic Leukemia 29

Anatomical Context for Chronic Myelomonocytic Leukemia

MalaCards organs/tissues related to Chronic Myelomonocytic Leukemia:

39
Bone, Bone Marrow, Monocytes, Myeloid, Neutrophil, Skin, T Cells

Publications for Chronic Myelomonocytic Leukemia

Articles related to Chronic Myelomonocytic Leukemia:

(show top 50) (show all 506)
id Title Authors Year
1
DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. ( 27733013 )
2017
2
Current management of patients with chronic myelomonocytic leukemia. ( 27849645 )
2017
3
Unplugging JAK/STAT in Chronic Myelomonocytic Leukemia. ( 26979390 )
2016
4
Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. ( 26848006 )
2016
5
Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. ( 27739921 )
2016
6
Age-related mutations and chronic myelomonocytic leukemia. ( 26648538 )
2016
7
Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia? ( 26879691 )
2016
8
Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. ( 26771811 )
2016
9
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). ( 27268068 )
2016
10
Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States. ( 27881041 )
2016
11
Leukemia Cutis in Chronic Myelomonocytic Leukemia. ( 26802766 )
2016
12
Chronic myelomonocytic leukemia mimicking hematologic systemic lupus erythematosus. ( 27365372 )
2016
13
Chronic myelomonocytic leukemia: molecularly contaminated, but not defined. ( 27063331 )
2016
14
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. ( 27385790 )
2016
15
Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia. ( 26851198 )
2016
16
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale. ( 27521328 )
2016
17
Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype. ( 27318442 )
2016
18
Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. ( 26922775 )
2016
19
When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. ( 27707735 )
2016
20
Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors. ( 27585952 )
2016
21
Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. ( 27480386 )
2016
22
In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia. ( 27157043 )
2016
23
A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia. ( 27406088 )
2016
24
Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. ( 27662201 )
2016
25
The fortuitous diagnosis of Burkitt lymphoma in a patient with chronic myelomonocytic leukemia. ( 26800105 )
2016
26
PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. ( 27521329 )
2016
27
Simultaneous Manifestation of Chronic Myelomonocytic Leukemia and Multiple Myeloma during Treatment by Prednisolone and Eltrombopag for Immune-Mediated Thrombocytopenic Purpura. ( 27597907 )
2016
28
Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. ( 27185207 )
2016
29
Fusion of platelet-derived growth factor receptor I^ to CEV14 gene in chronic myelomonocytic leukemia: A case report and review of the literature. ( 26870282 )
2016
30
Whole genome sequencing identified new somatic mutations for chronic myelomonocytic leukemia. ( 26875896 )
2016
31
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. ( 26849014 )
2016
32
A Multi-Institution Phase 1 Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). ( 26858309 )
2016
33
Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. ( 27337291 )
2016
34
Evolution of chronic myelomonocytic leukemia to myeloproliferative neoplasm. ( 27220638 )
2016
35
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. ( 27486981 )
2016
36
Clinical Prognostic Factors and Survival Outcome Of Chronic Myelomonocytic Leukemia: Reviewing 3,686 Patients. ( 27255661 )
2016
37
Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study. ( 26754557 )
2016
38
Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia. ( 27124934 )
2016
39
Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis. ( 27077763 )
2016
40
A variant c-KIT mutation, D816H, fundamental to the sequential development of an ovarian mixed germ cell tumor and systemic mastocytosis with chronic myelomonocytic leukemia. ( 27781377 )
2016
41
A Phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms and chronic myelomonocytic leukemia. ( 27551000 )
2016
42
TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia. ( 27777939 )
2016
43
Immunophenotypes of Chronic Myelomonocytic Leukemia (CMML) Subtypes by Flow Cytometry: a88A Comparison of CMML-1 vs CMML-2, Myeloproliferative vs Dysplastic, De Novo vs Therapy-Related, and CMML-Specific Cytogenetic Risk Subtypes. ( 27413139 )
2016
44
Chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia: a way to improve the outcome? ( 26790726 )
2016
45
Blastic plasmacytoid dendritic cell neoplasm associated with chronic myelomonocytic leukemia. ( 28092882 )
2016
46
Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. ( 25555161 )
2015
47
Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia. ( 26148174 )
2015
48
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. ( 25852055 )
2015
49
ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. ( 26001113 )
2015
50
A case of chronic myelomonocytic leukemia complicated with spondyloarthritis. ( 26392142 )
2015

Variations for Chronic Myelomonocytic Leukemia

Copy number variations for Chronic Myelomonocytic Leukemia from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 160282 22 11800000 24300000 Translocation Chronic myelomonocytic leukemia
2 228217 7 75001344 75206215 Translate HIP1 Chronic myelomonocytic leukemia
3 247204 9 129300000 140273252 Translocation Chronic myelomonocytic leukemia

Expression for Chronic Myelomonocytic Leukemia

Search GEO for disease gene expression data for Chronic Myelomonocytic Leukemia.

Pathways for Chronic Myelomonocytic Leukemia

Pathways related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.83 DNMT3A EZH2 KDM6A TET2
2 11.59 FLT3 JAK2 PDGFRB
3 11.51 ETV6 FLT3 KDM6A RUNX1
4 10.14 DNMT3A ETV6 FLT3

GO Terms for Chronic Myelomonocytic Leukemia

Cellular components related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.36 ASXL1 DNMT3A ETV6 EZH2 FLT3 HIP1

Biological processes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 regulation of gene expression GO:0010468 9.73 DNMT3A EZH2 KDM6A
2 protein autophosphorylation GO:0046777 9.7 FLT3 JAK2 PDGFRB
3 peptidyl-tyrosine phosphorylation GO:0018108 9.69 FLT3 JAK2 PDGFRB
4 response to estradiol GO:0032355 9.58 DNMT3A EZH2 PDGFRB
5 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.55 FLT3 PDGFRB
6 platelet-derived growth factor receptor signaling pathway GO:0048008 9.54 JAK2 PDGFRB
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.5 FLT3 JAK2 PDGFRB
8 DNA methylation GO:0006306 9.49 DNMT3A EZH2
9 homeostasis of number of cells GO:0048872 9.48 ASXL1 TET2
10 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.46 JAK2 PDGFRB
11 hematopoietic stem cell proliferation GO:0071425 9.43 ETV6 RUNX1
12 negative regulation of retinoic acid receptor signaling pathway GO:0048387 9.37 ASXL1 EZH2
13 positive regulation of MAP kinase activity GO:0043406 9.33 EZH2 FLT3 PDGFRB
14 myeloid progenitor cell differentiation GO:0002318 9.26 FLT3 TET2
15 hemopoiesis GO:0030097 9.26 ASXL1 FLT3 RUNX1 TET2
16 covalent chromatin modification GO:0016569 9.1 ASXL1 DNMT3A EZH2 JAK2 KDM6A TET2

Molecular functions related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.5 ASXL1 DNMT3A ETV6 EZH2 RUNX1 SETBP1
2 protein tyrosine kinase activity GO:0004713 9.43 FLT3 JAK2 PDGFRB
3 phosphatidylinositol 3-kinase binding GO:0043548 9.16 JAK2 PDGFRB
4 regulatory region DNA binding GO:0000975 8.62 EZH2 RUNX1

Sources for Chronic Myelomonocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....